Petra Acquisition Inc

-0.05 (-0.49%)
Products, Regulatory

Revelation Biosciences Receives Approval To Initiate Phase 2B Viral Challenge Study Of REVTx 99 For Prevention Of Respiratory Viral Infections

Published: 09/28/2021 13:20 GMT
Petra Acquisition Inc (PAIC) - Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of Revtx 99, an Experimental Prophylactic Treatment for Prevention of Respiratory Viral Infections.
Petra Acquisition Inc - Phase 2b Study Will Investigate Efficacy of Revtx-99 on Viral Load and Patient-reported Flu Symptoms.
Petra Acquisition Inc - Top-line Data Anticipated in Q2 of 2022.